OCULAR THERAPEUTIX, INC Earnings Per Share, Basic and Diluted
OCULAR THERAPEUTIX, INC (OCUL) reported Earnings Per Share, Basic and Diluted of -$2.56 per share for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-28.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-02-28
- OCULAR THERAPEUTIX, INC earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.64.
- OCULAR THERAPEUTIX, INC earnings per share, basic and diluted for the quarter ending 2020-03-31 was -$0.41.
- OCULAR THERAPEUTIX, INC earnings per share, basic and diluted for the quarter ending 2019-06-30 was -$0.57.
- OCULAR THERAPEUTIX, INC earnings per share, basic and diluted for the quarter ending 2019-03-31 was -$0.41.
- OCULAR THERAPEUTIX, INC earnings per share, basic and diluted for fiscal 2020 was -$2.56.
- OCULAR THERAPEUTIX, INC earnings per share, basic and diluted for fiscal 2019 was -$1.91.
- OCULAR THERAPEUTIX, INC earnings per share, basic and diluted for fiscal 2018 was -$1.57.
- OCULAR THERAPEUTIX, INC earnings per share, basic and diluted for fiscal 2017 was -$2.20.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$2.56 10-K · filed 2022-02-28 | |||
| 2020-06-30 | -$0.64 10-Q · filed 2020-08-07 | -$1.06 10-Q · filed 2020-08-07 | ||
| 2020-03-31 | -$0.41 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | -$1.91 10-K · filed 2022-02-28 | |||
| 2019-06-30 | -$0.57 10-Q · filed 2020-08-07 | -$0.98 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | -$0.41 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | -$0.42 10-K · filed 2019-03-07 | -$1.57 10-K · filed 2020-03-12 | ||
| 2018-09-30 | -$0.38 10-K · filed 2019-03-07 | -$1.15 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | -$0.37 10-Q · filed 2019-08-07 | -$0.76 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | -$0.40 10-K · filed 2019-03-07 | |||
| 2017-12-31 | -$0.44 10-K · filed 2019-03-07 | -$2.20 10-K · filed 2020-03-12 | ||
| 2017-09-30 | -$0.54 10-K · filed 2019-03-07 | -$1.76 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$0.64 10-K · filed 2019-03-07 | -$1.22 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | -$0.58 10-K · filed 2019-03-07 | |||
| 2016-12-31 | -$0.52 10-K · filed 2018-03-08 | -$0.90 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$1.36 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$1.80 10-K · filed 2019-03-07 |
| 2016-09-30 | -$0.39 10-K · filed 2018-03-08 | -$0.85 derived: net income ÷ weighted average shares · filed 2017-11-07 | -$1.29 10-Q · filed 2017-11-07 | -$1.72 derived: net income ÷ weighted average shares · filed 2018-03-08 |
| 2016-06-30 | -$0.46 10-Q · filed 2016-08-09 | -$0.90 10-Q · filed 2017-08-08 | -$1.33 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$1.80 derived: net income ÷ weighted average shares · filed 2018-03-08 |
| 2016-03-31 | -$0.44 10-K · filed 2018-03-08 | -$0.87 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$1.33 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$1.79 derived: net income ÷ weighted average shares · filed 2018-03-08 |
| 2015-12-31 | -$0.43 10-K · filed 2017-03-10 | -$0.90 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$1.35 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$1.71 10-K · filed 2018-03-08 |
| 2015-09-30 | -$0.47 10-K · filed 2017-03-10 | -$0.92 derived: net income ÷ weighted average shares · filed 2017-03-10 | -$1.28 10-Q · filed 2016-11-09 | -$1.65 derived: net income ÷ weighted average shares · filed 2017-03-10 |
| 2015-06-30 | -$0.45 10-K · filed 2017-03-10 | -$0.81 10-Q · filed 2016-08-09 | -$1.18 derived: net income ÷ weighted average shares · filed 2017-03-10 | -$1.64 derived: net income ÷ weighted average shares · filed 2017-03-10 |
| 2015-03-31 | -$0.35 10-K · filed 2017-03-10 | -$0.73 derived: net income ÷ weighted average shares · filed 2017-03-10 | -$1.18 derived: net income ÷ weighted average shares · filed 2017-03-10 | -$1.92 derived: net income ÷ weighted average shares · filed 2017-03-10 |
| 2014-12-31 | -$0.37 10-K · filed 2016-03-10 | -$0.83 derived: net income ÷ weighted average shares · filed 2017-03-10 | -$1.64 derived: net income ÷ weighted average shares · filed 2017-03-10 | -$2.69 10-K · filed 2017-03-10 |
| 2014-09-30 | -$0.48 10-K · filed 2016-03-10 | -$1.50 derived: net income ÷ weighted average shares · filed 2016-03-10 | -$2.93 10-Q · filed 2015-11-10 | -$4.08 derived: net income ÷ weighted average shares · filed 2016-03-10 |
| 2014-06-30 | -$2.10 10-K · filed 2016-03-10 | -$4.54 10-Q · filed 2015-08-10 | -$5.93 derived: net income ÷ weighted average shares · filed 2016-03-10 | -$7.31 derived: net income ÷ weighted average shares · filed 2016-03-10 |
| 2014-03-31 | -$2.45 10-K · filed 2016-03-10 | -$3.81 derived: net income ÷ weighted average shares · filed 2016-03-10 | -$5.18 derived: net income ÷ weighted average shares · filed 2016-03-10 | -$6.39 derived: net income ÷ weighted average shares · filed 2016-03-10 |
| 2013-12-31 | -$1.32 10-K · filed 2015-03-20 | -$2.66 derived: net income ÷ weighted average shares · filed 2016-03-10 | -$3.86 derived: net income ÷ weighted average shares · filed 2016-03-10 | -$5.11 10-K · filed 2016-03-10 |
| 2013-09-30 | -$1.34 10-K · filed 2015-03-20 | -$2.54 derived: net income ÷ weighted average shares · filed 2015-03-20 | -$3.79 10-Q · filed 2014-11-12 | |
| 2013-06-30 | -$1.19 10-K · filed 2015-03-20 | -$2.45 10-Q · filed 2014-08-29 | ||
| 2013-03-31 | -$1.26 10-K · filed 2015-03-20 | |||
| 2012-12-31 | -$5.60 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |